

TAKE A DEEP BREATH

Albuterol is most commonly administered as an inhaled medication using a metered-dose inhaler with a spacer device or a nebulizer.

FOCUS ON

Albuterol Sulfate for Cats

Tekla Lee-Fowler, DVM, MS, DACVIM (SAIM)
Auburn University College of Veterinary Medicine

Albuterol, also known as salbutamol, is a bronchodilator that is indicated as a rescue therapy for acute feline asthma exacerbations. This medication comes in various formulations; the most frequently used is inhaled albuterol delivered using either a metered-dose inhaler or a nebulizer. Albuterol is also available in an oral formulation that is infrequently prescribed in cats.

When albuterol is used in a metered-dose inhaler, it is typically administered with the aid of a facemask and spacer (such as the AeroKat; Trudell Animal Health, trudellanimalhealth.com); therefore, training a cat to accept a facemask and spacer prior to the need for drug administration maximizes success with this modality. When a cat is under general anesthesia and requires bronchodilator therapy, inhaled albuterol can be directly administered into the endotracheal tube using either a metered-dose inhaler or a nebulizer.

MECHANISM OF ACTION

Albuterol is a selective, short-acting β_2 agonist that acts on β_2 adrenergic receptors to relax airway smooth muscle. Binding of albuterol to the β_2 adrenergic receptors on airway smooth muscle cells causes activation of adenylyl cyclase, resulting in increased

production of intracellular cyclic 3',5'-adenosine monophosphate (cyclic AMP). Cyclic AMP activates protein kinase A, which inhibits phosphorylation of myosin and results in lower concentrations of intracellular ionic calcium. This results in bronchial, and likely to a lesser extent tracheal, smooth muscle relaxation.^{1,2}

EFFICACY

Albuterol is a mainstay of asthma treatment in human medicine with documented efficacy for short-term bronchodilation. In cats, data are limited to studies of experimentally induced asthma. Studies in cats evaluated salbutamol (albuterol) alone or in combination with ipratropium bromide, an acetylcholine antagonist also used as a bronchodilator. Results of these studies were mixed. A study in 2005 evaluating the use of salbutamol and/or ipratropium bromide found reduced bronchoconstriction associated with bronchoalveolar lavage (BAL) when the combination medication was administered.³ In a group of healthy cats evaluated in 2009, salbutamol appeared to be effective prevention for muscarinic-induced bronchoconstriction.⁴ However, a study in 2010 evaluated salbutamol alone and the combination of salbutamol and ipratropium bromide in a group of cats



sensitized to *Ascaris suum* with allergen-induced bronchoconstriction. In this group, salbutamol and the combination product both had limited efficacy in reversing the bronchoconstriction.⁵

Data in clinically affected cats are lacking. In the author's clinical experience, inhaled albuterol is efficacious for rescue therapy delivered with a metered-dose inhaler with a facemask and spacer, as a nebulized treatment, or, in intubated patients, with either a metered-dose inhaler or nebulizer through an endotracheal tube.

CLINICAL APPLICATIONS

As a rescue therapy, bronchodilators are indicated when there is clinical evidence of bronchoconstriction. Bronchoconstriction is a primary feature of feline asthma. It is important to note that bronchodilators do not address the underlying airway inflammation; therefore, they should not be used as a sole therapy but in combination with medications to address the underlying inflammatory airway disease. Clinical signs that support the presence of bronchoconstriction include increased respiratory effort on exhalation and wheezes upon thoracic auscultation. Increased expiratory effort can be noted by looking for increased abdominal effort during exhalation and a slightly prolonged phase of exhalation compared with the inspiratory phase. Suspicion for bronchoconstriction can also be raised on thoracic radiographs when lung hyperinflation and flattening of the diaphragm are noted.

Albuterol is primarily indicated as a rescue inhaler during acute asthma exacerbations. Overuse of albuterol can result in increased airway inflammation and hyperreactivity or paradoxical bronchospasm, a serious, potentially fatal complication described in human medicine. Desensitization to albuterol can also occur with high doses and long-term use. These risks are described further under **Adverse Reactions**. Therefore, it is imperative to directly treat the underlying airway inflammation associated with feline asthma through glucocorticoid administration and reserve albuterol use for rescue therapy.

Administration via a metered-dose inhaler with a facemask and spacer is ideal for at-home use. Nebulized albuterol solution for inhalation is sometimes easier to administer in the hospital setting, particularly to a patient experiencing respiratory distress. It should be

Clinical signs that support the presence of bronchoconstriction include increased respiratory effort on exhalation and wheezes upon thoracic auscultation.

noted that while dry powder inhaler formulations are available for human use, they are not suited for use in cats as they cannot be used with a facemask and spacer.

It is also recommended that cats undergoing bronchoscopy and BAL receive bronchodilator therapy. In the author's hospital, this is included as part of the premedication procedure. Albuterol can be used for this purpose. In 2005, a study described airflow limitation induced by bronchoscopy and BAL in both healthy cats and cats with experimentally induced asthma; airflow limitation was worse in cats with airway inflammation but was noted even in healthy cats.³ Therefore, bronchodilator therapy is recommended for all cats undergoing this procedure.

RECOMMENDED DOSAGE

Albuterol sulfate is most commonly administered as an inhalant medication. Oral doses are also provided; however, studies evaluating oral efficacy in cats are not available. As noted above, long-term use of inhaled albuterol and use as a sole therapy are not recommended.

Albuterol sulfate metered-dose inhalers typically provide 90 µg/actuation (puff). It is recommended to administer 1 to 3 puffs once every 12 to 24 hours as needed for rescue therapy.¹

Albuterol sulfate inhalation solution is designed to be delivered via a nebulizer. Several concentrations of this solution are available. The author uses the 0.5% (5 mg/mL) preservative-free solution and dilutes 1.25 mg (0.25 mL) of solution in 2 mL of sterile 0.9% NaCl. This results in a similar concentration, but with lower volume, to that reported by Leemans et al. in 2009.⁴ The dose is placed in the nebulizer cup and administered via nebulization. Nebulized salbutamol at

a dose of 3.75 mg in 6 mL saline was evaluated in one study of cats with experimentally induced asthma and found to be efficacious.⁴ The author uses the lower volume detailed above as it has been efficacious in a clinical setting.

Oral albuterol can be administered at a dose of 0.02 to 0.05 mg/kg once every 8 to 12 hours.¹ Tablets and a syrup formulation are also available.

PHARMACOKINETICS

The pharmacokinetics of albuterol are largely based on data from human studies. There are no available studies of albuterol pharmacokinetics in cats.

One study has been recently published using a computer model to evaluate distribution of inhaled salbutamol.⁶ While the perceived advantage of administering inhaled albuterol is delivery of the drug directly to the target area, there is considerable variation in distribution of the drug. Distribution of inhaled salbutamol (albuterol) in cats was evaluated using computational fluid dynamics. This study demonstrated that when a facemask and spacer was used to deliver albuterol with a metered-dose inhaler, a large amount of the medication was deposited in the device and in the upper airway; only between 5.8% and 25.8% of the medication reached the lungs.⁶

ADVERSE REACTIONS

Albuterol is selective for β_2 receptors, and fewer adverse effects are expected than with nonselective β agonists. Inhaled formulations at therapeutic doses are also thought to be associated with fewer adverse effects than systemic formulations. However, high doses of albuterol may result in hypokalemia, tachycardia, arrhythmias, and hypertension. Hyperglycemia, anxiousness, and muscle tremors are also possible.⁷ Diabetic patients receiving albuterol may experience hyperglycemia; therefore, diabetic control should be monitored. Albuterol inhibits uterine contractions at the end of gestation and should be avoided when possible in pregnant animals.⁷ Overdose is unlikely in cats receiving therapeutic doses. Recommended monitoring for cats receiving albuterol includes heart rate, heart rhythm, blood pressure, and potassium and blood glucose concentrations.

β_2 receptors are membrane-associated receptors, and with repeated or high dosing, these receptors can

internalize. This results in fewer receptors available on the membrane surface to bind with albuterol, leading to desensitization to this medication, or tachyphylaxis. Long-term exposure can eventually result in downregulation of receptor mRNA, also resulting in fewer receptors. Desensitization ultimately results in less bronchodilation in response to albuterol administration, and this decreased efficacy can result in more frequent need for albuterol treatment.¹

Albuterol is a 50:50 racemic mixture of 2 chemical enantiomers, or 2 molecules that are mirror images of each other in their chemical structure: R-albuterol and S-albuterol. The R-albuterol enantiomer is the more pharmacologically active molecule responsible for the bronchodilatory effects of albuterol, while the S-albuterol enantiomer was long thought to be inert. Further study has revealed that while the S-albuterol enantiomer does not contribute to airway smooth muscle relaxation at therapeutic doses of racemic albuterol, it is not entirely inert. There is evidence in human medicine that the S-albuterol enantiomer is associated with increased airway inflammation and hyperreactivity. Furthermore, the S-albuterol enantiomer has a longer half-life and may accumulate in the airways to a greater extent. It is thought that the potential for accumulation of this enantiomer within the airway may play a role in paradoxical bronchospasm.⁸ A 2009 study in healthy cats and cats with experimentally induced feline asthma demonstrated increased airway inflammation in both healthy and asthmatic cats receiving the racemic mixture of albuterol.⁹ A pure R-albuterol enantiomer form is available as the medication levalbuterol; however, this medication tends to be more expensive, and in human medicine, controversy exists as to whether it results in a significant difference in clinical outcome compared with racemic albuterol.

CONTRAINDICATIONS

Albuterol is contraindicated in patients with hypersensitivity to albuterol or components of the formulation used.

DRUG INTERACTIONS

Albuterol should not be coadministered with sympathomimetic amines, tricyclic antidepressants, and monoamine inhibitors. Extreme caution should be used in patients also receiving monoamine oxidase inhibitors or tricyclic antidepressants.¹⁰



Coadministration of albuterol tablets and oral sympathomimetics is not recommended. Coadministration with methylxanthines should be avoided, as reports of cardiac arrhythmias and sudden death have been associated with this combination.¹⁰ Patients receiving diuretic therapy may be at increased risk of hypokalemia; therefore, potassium should be monitored.

SUMMARY

Albuterol is indicated for treatment of bronchoconstriction in cats with feline asthma. It is available in several formulations but is most commonly administered as an inhaled medication using a metered-dose inhaler with a spacer device or a nebulizer. To avoid promoting airway inflammation and potential tachyphylaxis, inhaled formulations should be used only as a rescue therapy. While few direct contraindications to albuterol use exist, significant drug interactions exist and should be avoided. **TVP**

References

- Boothe DM. Drugs affecting the respiratory system. In: Boothe DM, ed. *Small Animal Clinical Pharmacology & Therapeutics*. 2nd ed. St. Louis, MO: Elsevier Saunders; 2012:745-782.
- O'Donnell SR, Wanstall JC. Relaxation of cat trachea by β -adrenoreceptor agonists can be mediated by both β_1 - and β_2 -adrenoreceptors and potentiated by inhibitors of extraneuronal uptake. *Br J Pharmacol*. 1983;78(2):417-424.
- Kirschvink N, Leemans J, Delvaux F, et al. Bronchodilators in bronchoscopy-induced airflow limitation in allergen-sensitized cats. *J Vet Intern Med*. 2005;19(2):161-167.
- Leemans J, Kirschvink N, Bernaerts F, et al. A pilot study comparing the antispasmodic effects of inhaled salmeterol, salbutamol and ipratropium bromide using different aerosol devices on muscarinic bronchoconstriction in healthy cats. *Vet J*. 2009;180(2):236-245.
- Leemans J, Kirschvink N, Clercx C, et al. Functional response to inhaled salbutamol and/or ipratropium bromide in Ascaris suum-sensitized cats with allergen-induced bronchospasms. *Vet J*. 2010;186(1):76-83.
- Fernández-Parra R, Pey P, Reiner C, Malvé M. Salbutamol transport and deposition in the upper and lower airway with different devices in cats: a computational fluid dynamics approach. *Animals (Base)*. 2021;11(8):2431.
- Papich MG. Albuterol sulfate. In: Papich MG, ed. *Papich Handbook of Veterinary Drugs*. 5th ed. St. Louis, MO: Elsevier Saunders; 2020:16-18
- Page CP, Morley J. Contrasting properties of albuterol stereoisomers. *J Allergy Clin Immunol*. 1999;104 (2 Pt 2):S31-S41.
- Reinero CR, Delgado C, Spinka C, et al. Enantiomer-specific effects of albuterol on airway inflammation in healthy and asthmatic cats. *Int Arch Allergy Immunol*. 2009;150(1):43-50.
- Veterinary Information Network. Albuterol. *Veterinary Drug Handbook*. Accessed July 21, 2022. vin.com/members/cms/project/defaultadv1.aspx?pld=13468&id=7389479

Tekla Lee-Fowler

Dr. Lee-Fowler is an associate professor in small animal internal medicine in the department of clinical sciences at Auburn University. She is a graduate of Mississippi State University College of Veterinary Medicine. Dr. Lee-Fowler completed a residency in small animal internal medicine at the University of Missouri College of Veterinary Medicine and is a diplomate of the American College of Veterinary Internal Medicine. Her research primarily focuses on respiratory disease diagnostics and therapies with a secondary interest in obesity research.



Mirataz[®]

(mirtazapine transdermal ointment)

For topical application in cats only. Not for oral or ophthalmic use.

CAUTION: Federal law (USA) restricts this drug to use by or on the order of a licensed veterinarian.

Before using this product, please consult the product insert, a summary of which follows:

INDICATION: Mirataz is indicated for the management of weight loss in cats.

DOSAGE AND ADMINISTRATION: Administer topically by applying a 1.5-inch ribbon of ointment (approximately 2 mg/cat) on the inner pinna of the cat's ear once daily for 14 days. Wear disposable gloves when applying Mirataz. Alternate the daily application of Mirataz between the left and right inner pinna of the ears. **See Product Insert for complete dosing and administration information.**

CONTRAINDICATIONS: Mirataz is contraindicated in cats with a known hypersensitivity to mirtazapine or to any of the excipients. Mirataz should not be given in combination, or within 14 days before or after treatment with a monoamine oxidase inhibitor (MAOI) [e.g. selegiline hydrochloride (L-deprenyl), amitraz], as there may be an increased risk of serotonin syndrome.

HUMAN WARNINGS: Not for human use. Keep out of reach of children. **Wear disposable gloves when handling or applying Mirataz to prevent accidental topical exposure.** After application, dispose of used gloves and wash hands with soap and water. After application, care should be taken that people or other animals in the household do not come in contact with the treated cat for 2 hours because mirtazapine can be absorbed transdermally and orally. However, negligible residues are present at the application site and the body of the cat at 2 hours after dosing. In case of accidental skin exposure, wash thoroughly with soap and warm water. In case of accidental eye exposure, flush eyes with water. If skin or eye irritation occurs seek medical attention. In case of accidental ingestion, or if skin or eye irritation occurs, seek medical attention.

PRECAUTIONS: Do not administer orally or to the eye. Use with caution in cats with hepatic disease. Mirtazapine may cause elevated serum liver enzymes (See **Animal Safety** in the product insert). Use with caution in cats with kidney disease. Kidney disease may cause reduced clearance of mirtazapine which may result in higher drug exposure. Upon discontinuation of Mirataz, it is important to monitor the cat's food intake. Food intake may lessen after discontinuation of mirtazapine transdermal ointment. If food intake diminishes dramatically (>75%) for several days, or if the cat stops eating for more than 48 hours, reevaluate the cat. Mirataz has not been evaluated in cats < 2 kg or less than 6 months of age. The safe use of Mirataz has not been evaluated in cats that are intended for breeding, pregnant, or lactating cats.

ADVERSE REACTIONS: In a randomized, double-masked, vehicle-controlled field study to assess the effectiveness and safety of mirtazapine for the management of weight loss in cats, 115 cats treated with Mirataz and 115 cats treated with vehicle control were evaluated for safety. The vehicle control was an ointment containing the same inert ingredients as Mirataz without mirtazapine. The most common adverse reactions included application site reactions, behavioral abnormalities (vocalization and hyperactivity), and vomiting. **See Product Insert for complete Adverse Reaction information.** To report suspected adverse events, for technical assistance or to obtain a copy of the SDS, contact Dechra at 888-933-2472. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at <http://www.fda.gov/reportanimalae>.

EFFECTIVENESS: The effectiveness of Mirataz (mirtazapine transdermal ointment) was demonstrated in a randomized, double-masked, vehicle-controlled, multi-site field study involving client-owned cats of various breeds. Enrolled cats were \geq 1 year of age and had existing documented medical history of \geq 5% weight loss deemed clinically significant. The most common pre-existing conditions included renal insufficiency, vomiting, and hyperthyroidism. Some cats had more than one pre-existing condition. Cats were randomized to treatment groups in a 1:1 ratio of Mirataz to vehicle control. A total of 230 cats were enrolled and received either Mirataz (115 cats) or a vehicle control (115 cats) containing the same inert ingredients without mirtazapine. The cats were 2.8-24.6 years of age and weighed 2.1-9.2 kg. The dosage was a 1.5-inch ribbon (approximately 2 mg/cat) mirtazapine or vehicle ointment administered topically to the inner pinna of the cat's ear. A total of 177 cats were determined to be eligible for the effectiveness analysis; 83 cats were in the Mirataz group and 94 cats were in the vehicle control group. The primary effectiveness endpoint was the mean percent change in body weight from Day 1 to the Week 2 Visit. At Week 2, the mean percent increase in body weight from Day 1 was 3.94% in the mirtazapine group and 0.41% in the vehicle control group. The difference between the two groups was significant ($p < 0.0001$) based on a two-sample t-test assuming equal variances. A 95% confidence interval on the mean percent change in body weight for the Mirataz group is (2.77, 5.11), demonstrating that the mean percent change is statistically different from and greater than 0.

STORAGE: Store below 25°C (77°F). Multi-use tube. Discard within 30 days of first use.

HOW SUPPLIED: Mirataz is supplied in a 5 gram aluminum tube.

MANUFACTURED FOR:
Dechra Veterinary Products
7015 College Boulevard, Suite 525
Overland Park, KS 66211 USA

US Patent 10,603,272

Approved by FDA under NADA # 141-481
NDC 86078-686-01

Rev. August 2020
Mirataz[®] is a trademark of Dechra Limited.
©2020 Dechra Veterinary Products.
All rights reserved.

